<DOC>
	<DOC>NCT00982267</DOC>
	<brief_summary>The purpose of this study is to define the Maximum tolerated dose of SU14813 when administered as single agent in patients with solid tumors.</brief_summary>
	<brief_title>A Trial Of SU14813 In Patients With Advanced Solid Malignancies</brief_title>
	<detailed_description />
	<criteria>Patients with a histologically proven advanced solid malignancy for which no recognized therapy was available or for which standard therapy had failed Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 Serum albumin â‰¥3.0 g/dL and adequate haemopoietic, renal and liver function Chemotherapy within 3 weeks (6 weeks for nitrosoureas or mitomycin C) or radiotherapy or an investigational agent within 4 weeks before the start of study treatment Subjects had to have recovered from all prior treatment toxicities, except alopecia, and from any major surgery.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2011</verification_date>
	<keyword>cancer</keyword>
</DOC>